Inhibikase Therapeutics (IKT) Operating Income (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Operating Income for 7 consecutive years, with -$17.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 22.22% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$55.2 million (down 43.78% YoY), while the FY2025 annual figure was -$52.0 million, down 81.8% from the prior year.
• Operating Income declined to -$17.8 million in Q1 2026 per IKT's latest filing, from -$13.8 million in the prior quarter.
• Across five years, Operating Income topped out at -$4.3 million in Q4 2022 and bottomed at -$17.8 million in Q1 2026.
• Historically, Operating Income has averaged -$8.0 million across 5 years, with a median of -$5.1 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Income gained 18.57% — and 2025, when it slumped 205.25%.
• Inhibikase Therapeutics' Operating Income stood at -$4.3 million in 2022, then declined by 1.58% to -$4.4 million in 2023, then slumped by 193.6% to -$12.9 million in 2024, then retreated by 6.55% to -$13.8 million in 2025, then fell by 29.52% to -$17.8 million in 2026.
• Business Quant data shows IKT's Operating Income at -$17.8 million in Q1 2026, -$13.8 million in Q4 2025, and -$12.8 million in Q3 2025.